# Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas

> **NCT05101148** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 24 (actual)

## Conditions studied

- Neurofibromatosis Type 1

## Interventions

- **DRUG:** Selumetinib

## Key facts

- **NCT ID:** NCT05101148
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-07-21
- **Primary completion:** 2022-04-06
- **Final completion:** 2028-04-28
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2026-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05101148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05101148, "Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05101148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*